GLPG
Galapagos NV
Company Overview
| Mkt Cap | $2.08B | Price | $31.69 |
| Volume | 59.91K | Change | -2.70% |
| P/E Ratio | 28.1 | Open | $32.25 |
| Revenue | $275.6M | Prev Close | $32.57 |
| Net Income | $74.1M | 52W Range | $22.36 - $37.78 |
| Div Yield | N/A | Target | $32.50 |
| Overall | 58 | Value | 60 |
| Quality | 34 | Technical | 81 |
No chart data available
About Galapagos NV
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | GLPG | $31.69 | -2.7% | 59.91K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |